JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 125 filers reported holding JOUNCE THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 6.50 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $31,959 | -55.0% | 28,791 | -5.1% | 0.00% | -100.0% |
| Q3 2022 | $71,000 | -91.6% | 30,350 | -89.1% | 0.00% | -85.7% |
| Q2 2022 | $842,000 | -60.7% | 278,031 | -12.0% | 0.01% | -50.0% |
| Q1 2022 | $2,145,000 | -3.8% | 315,866 | +18.3% | 0.01% | -6.7% |
| Q4 2021 | $2,230,000 | +158.4% | 267,032 | +110.5% | 0.02% | +150.0% |
| Q2 2021 | $863,000 | -34.3% | 126,857 | -0.9% | 0.01% | -40.0% |
| Q1 2021 | $1,314,000 | +86.4% | 127,985 | +27.0% | 0.01% | +66.7% |
| Q4 2020 | $705,000 | -52.7% | 100,743 | -44.9% | 0.01% | -60.0% |
| Q3 2020 | $1,492,000 | +19.6% | 182,837 | +1.2% | 0.02% | +7.1% |
| Q2 2020 | $1,247,000 | +50.2% | 180,748 | +3.4% | 0.01% | +27.3% |
| Q1 2020 | $830,000 | -30.5% | 174,749 | +27.7% | 0.01% | -8.3% |
| Q4 2019 | $1,195,000 | +331.4% | 136,895 | +64.6% | 0.01% | +300.0% |
| Q3 2019 | $277,000 | -9.5% | 83,166 | +34.6% | 0.00% | -25.0% |
| Q2 2019 | $306,000 | +218.8% | 61,766 | +298.5% | 0.00% | +300.0% |
| Q1 2019 | $96,000 | – | 15,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRV GP II, LLC | 1,347,829 | $9,152,000 | 93.42% |
| Ally Bridge Group (NY) LLC | 550,000 | $3,735,000 | 2.77% |
| ACUTA CAPITAL PARTNERS, LLC | 813,500 | $5,524,000 | 2.58% |
| TRV GP III, LLC | 1,148,780 | $7,800,000 | 2.12% |
| Deep Track Capital, LP | 4,259,653 | $28,923,000 | 1.86% |
| Logos Global Management LP | 1,400,000 | $9,506,000 | 1.23% |
| PFM Health Sciences, LP | 3,972,868 | $26,976,000 | 1.01% |
| Sofinnova Investments, Inc. | 1,481,219 | $10,057,000 | 0.76% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 248,347 | $1,686,000 | 0.70% |
| RTW INVESTMENTS, LP | 4,680,412 | $31,780,000 | 0.66% |